Nykode Therapeutics Asa · OSL:NYKD
Nykode Therapeutics Asa — Q4 2024 Earnings Presentation
24 slides from Nykode Therapeutics Asa's earnings presentation, Feb 26, 2025
Slide 1: Q4 2024 Results Presentation
Q4 2024 Results Presentation February 26, 2024
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Today's presenters from Nykode
Today’s presenters from Nykode MICHAEL ENGSIG AGNETE FREDRIKSEN HARALD GURVIN Chief Executive Officer Chief Scientific Officer & Chief Financial Officer Business Development Nykode Therapeutics | Q4 '24 webcast | Non-confidential 3
Slide 4: Highlights
Highlights • Strategic refocus to realign financial resources and cash runway with organizational priorities. • Targeting an annual cost base of ~$20m and extending the cash runway into 2030. • Strong cash position of $115.4m at December 31, 2024. • Published final Phase 2 data from the VB-C-02 tria
Slide 5: Balancing financial position, capital market sentiment and focus on most valuable assets
Balancing financial position, capital market sentiment and focus on most valuable assets and value generators Nykode is a lean research-focused organization focused at discovering novel assets aimed at creating exciting investment opportunities through targeted development activities and early partn
Slide 6: VB10.16 – Therapeutic vaccine candidate for HPV16+ cancers
VB10.16 – Therapeutic vaccine candidate for HPV16+ cancers OPPORTUNITY AND UNMET NEED SUPPORTING RATIONALE Unmet need for further improved survival outcomes with well- VB10.16 + atezolizumab strong efficacy across all endpoints tolerated treatment alternatives and favourable safety profile in ad
Slide 7: VB10.16 C-02 data compare strongly to CPI monotherapy as well as expected SoC
VB10.16 C-02 data compare strongly to CPI monotherapy as well as expected SoC in ≥2L r/m cervical cancer CPI Monotherapy in r/m CC VB10.16 plus atezolizumab Atezolizumab in Pembrolizumab Cemiplimab in Tisotumab vedotin in PD-L1+*** PD-L1+††† in PD-L1+** PD-L1+ †† (PD-L1 agnostic) ‡ ‡ Skyscraper-04,
Slide 8: VB-C-02 Ph2 trial: Strong efficacy with survival benefit
VB-C-02 Ph2 trial: Strong efficacy with survival benefit Subgroup identified with best responese (PD-L1+, >1 line of prior therapy) PD-L1+ with 1 prior line Endpoint Population ALL (N=47) PD-L1+ (N=24) of therapy (N=15) ORR (%) EAS 19% 29% 40% mPFS (mos) EAS 4.1 6.3 15.8 mOS (mos) EAS 21.3 24.7 NR O
Slide 9: VB10.NEO – Nykode's individualized cancer vaccine
VB10.NEO – Nykode’s individualized cancer vaccine COMMERCIAL OPPORTUNITY SUPPORTING RATIONALE Potential to address broad set of indications (all tumor Broad and long-lasting T cell responses generated in 2 types) clinical trials in heavily pre-treated patients with metastatic Strategic focus a
Slide 10: Preliminary data from VB-N-02 confirms VB10.NEO's potential
Preliminary data from VB- N-02 confirms VB10.NEO’s potential Preliminary immunogenicity data from the VB-N-02 trial1 confirms earlier observations from the N-01 trial: 100 85 85 88 58 VB-N-01 45 VB-N-02 % immunogenic NeoAG % of patients with at % of patients with at least 1 least 1 de novo response
Slide 11: Nykode's neoantigen vaccine elicits durable responses
Nykode’s neoantigen vaccine elicits durable responses Nykode’s neoantigen mRNA vaccine leads to durable immune responses that are efficiently boosted after more than 100 days Pre-Boost Post-Boost Two vaccinations (D0, D21) Three vaccinations (D0, D21, D132) Pre-Boost Post-Boost Increase T cell respo
Slide 12: Durable responses are functional
Durable responses are functional Nykode’s neoantigen mRNA vaccine elicits durable responses that protect from tumor challenge on day 90 Control Nykode neoantigen vaccine Tumor development Tumor volume (mm3) 2000 2000 100 Tumor volume (mm3) 1500 1500 75 % Tumor take Dilution buffer (1) Single Vaccina
Slide 13: Immune-Tolerance – Nykode's APC targeted platform
Immune-Tolerance – Nykode’s APC targeted platform uniquely positioned to target antigens to tolerizing DCs OPPORTUNITY AND UNMET NEED SUPPORTING RATIONALE Opportunities within autoimmune diseases, Pre-clinical PoC data in autoimmune disease allergies and organ transplant rejection models show po
Slide 14: Nykode vaccine targeting different receptors on APCs is effective in EAE
Nykode vaccine targeting different receptors on APCs is effective as early therapeutic in EAE EAE MODEL – EARLY THERAPEUTIC DELIVERY Target 1 Target 1 Target 2 Tol Paralysis ✱✱✱ APC 5 Targeted 1 ✱✱ MOG MOG Targeted 2 50 (27-63) (27-63) 4 PBS Target 2 Targeted Targeted 40 EAE score vaccine 1 vaccine
Slide 15: APC targeting is required for effective early therapy of EAE disease
APC targeting is required for effective early therapy of EAE disease EAE MODEL – EARLY THERAPEUTIC DELIVERY 30 µg 10 µg 3 µg Tol. Targeted APC 4 Non-targeted 4 5 PBS 4 EAE score (0-8) EAE score (0-8) EAE score (0-8) 3 3 3 2 2 2 1 1 1 0 0 0 MOG MOG * 10 12 14 16 20 22 24 26 28 6 8 * 10 12 14 16 20 22
Slide 16: APC targeting is required for potent and prolonged effect of vaccine to second target
APC targeting is required for potent and prolonged effect of vaccine to second target as early therapy in EAE EAE MODEL – EARLY THERAPEUTIC DELIVERY Target 1 30 µg 10 µg 3 µg Tol 3.5 Targeted 2 Non-targeted 3.5 3.5 APC 3.0 PBS 3.0 3.0 EAE score (0-8) EAE score (0-8) EAE score (0-8) 2.5 2.5 2.5 Targe
Slide 17: Early therapeutic treatment alleviates disease progression in relapsing-remitting EAE
Early therapeutic treatment with Nykode vaccine alleviates disease progression in relapsing-remitting EAE RELAPSING-REMITTING EAE MODEL – EARLY THERAPEUTIC DELIVERY PLP (139-151) recall assay using splenocytes, day 35 3 Proteolipid protein Targeted PLP(139-151) PBS ✱✱ IL-17 100 ✱✱ EAE score (0-8) 15
Slide 18: New data to be presented
New data to be presented February 25-27, 2025 | Boston Nykode Therapeutics | Q4 '24 webcast | Non-confidential 18
Slide 19: Q4 2024 Financial Results
Q4 2024 Financial Results
Slide 20: Income Statement
Income Statement Revenue from contracts with customers Amounts in USD ‘000 Q4 2024 Q4 2023 YTD 2024 YTD 2023 • R&D activities under Genentech and Regeneron Revenue from contracts with customers 6,773 2,191 8,679 12,902 agreements Other income 121 89 479 421 • Increase in Q4 2024 due to termination o
Slide 21: Balance Sheet
Balance Sheet Cash and cash equivalents Amounts in USD ‘000 31/12/2024 31/12/2023 • Strong cash position of $115.4m at December 31, ASSETS 2024 Non-current assets Other non-current receivables Property, plant and equipment 3,741 4,413 Right-of-use assets 4,001 6,104 • Mainly reflects the NOK 325 mil
Slide 22: Balance Sheet - contd.
Balance Sheet - contd. Amounts in USD ’000 31/12/2024 31/12/2023 Equity EQUITY AND LIABILITIES • Total equity of $136.2m as per December 31, 2024 Equity Share capital 367 367 • Equity ratio of 89% Share premium 128,986 128,986 Other capital reserves 18,683 15,395 Other components of equity (3,060) (
Slide 23: Our priorities for 2025
Our priorities for 2025 Cost discipline & extended runway • Continue implementation of refocused strategy aligning financial resources and cash runway with new organizational priorities. • Aiming at cost base ~USD 20m per annum, extending cash runway into 2030. Pipeline optimization • Execute the VB
Slide 24: Unlocking the future of medicine
UNLOCKING THE FUTURE OF MEDICINE Contact: Alexandra Deschner Head of Investor Relations IR@nykode.com Nykode Therapeutics | Q4 '24 webcast | Non-confidential
Nykode Therapeutics As — Q4 2024 Earnings Presentation on 6ix